|
WO2021055863A1
|
|
Pyruvate kinase r (pkr) activating compositions
|
|
WO2021055807A1
|
|
Activating pyruvate kinase r
|
|
WO2021003163A1
|
|
Treating cancer with a bromodomain and extra-terminal (bet) family inhibitor
|
|
US2020297717A1
|
|
INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
|
|
WO2020232381A1
|
|
INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
|
|
WO2020191022A1
|
|
Inhibiting ubiquitin specific peptidase 9x
|
|
WO2020190792A1
|
|
Compositions and methods for treating androgen receptor positive forms of cancer
|
|
WO2020190791A1
|
|
Inhibiting cyclic amp-responsive element-binding protein (creb)
|
|
WO2020190780A1
|
|
Inhibiting cyclic amp-responsive element-binding protein (creb)
|
|
WO2020139988A1
|
|
Compositions for inhibiting ubiquitin specific protease 1
|
|
WO2020139916A1
|
|
Inhibiting ubiquitin specific peptidase 9x
|
|
WO2020092376A1
|
|
Treating non-alcoholic steatohepatitis (nash)
|
|
US2020131155A1
|
|
Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
|
|
WO2020077071A1
|
|
Inhibiting fatty acid synthase (fasn)
|
|
TW202026283A
|
|
Inhibiting fatty acid synthase (fasn)
|
|
CA3110113A1
|
|
Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
|
|
US2020087309A1
|
|
Activating pyruvate kinase r and mutants thereof
|
|
US2020129485A1
|
|
Treating sickle cell disease with a pyruvate kinase r activating compound
|
|
CA3113423A1
|
|
Inhibiting ubiquitin specific peptidase 9x
|
|
WO2020061252A1
|
|
Inhibiting ubiquitin specific peptidase 9x
|
